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eural plasticity is a fundamental process that
allows the brain to receive information and form appro-
priate adaptive responses to the same or similar stimuli.
The molecular and cellular adaptations underlying learn-
ing and memory are the best-characterized and most-
studied examples of neural plasticity. However, many
different stimuli can activate neural plasticity processes
in different brain structures, including environmental,
social, behavioral, and pharmacological stimuli. In fact,
it could be argued that neural plasticity is one of the
most essential and important processes that the brain
performs as it relates to many types of central nervous
system functions.
Thus,disrupted or abnormal plasticity could lead to mal-
adaptive neuronal responses and abnormal behavior.
This could occur in response to genetic abnormalities of
the cellular machinery required for plasticity,and abnor-
mal or inappropriate stimuli. For example, exposure to
inappropriate or prolonged stress has been reported to
alter molecular and cellular markers of neural plasticity,
and could contribute to stress-related mood disorders.
This review will discuss the literature demonstrating
altered neural plasticity in response to stress, and clini-
cal evidence indicating that altered plasticity occurs in
depressed patients.The second part of the review will
present evidence that antidepressant treatment blocks
the effects of stress or produces plasticity-like responses.
General mechanisms of neural plasticity
Neural plasticity encompasses many different types of
molecular and cellular responses that occur when cells
in the brain are induced to respond to inputs from other
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Neural plasticity is emerging as a fundamental and crit-
ical mechanism of neuronal function, which allows the
brain to receive information and make the appropriate
adaptive responses to subsequent related stimuli.
Elucidation of the molecular and cellular mechanisms
underlying neural plasticity is a major goal of neuro-
science research, and significant advances have been
made in recent years. These mechanisms include regula-
tion of signal transduction and gene expression, and also
structural alterations of neuronal spines and processes,
and even the birth of new neurons in the adult brain.
Altered plasticity could thereby contribute to psychiatric
and neurological disorders. This article reviews the liter-
ature demonstrating altered plasticity in response to
stress, and evidence that chronic antidepressant treat-
ment can reverse or block the effects, and even induce
neural plasticity-like responses. Continued elucidation of
the mechanisms underlying neural plasticity will lead to
novel drug targets that could prove to be effective and
rapidly acting therapeutic interventions.  
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(e-mail: ronald.duman@yale.edu)cells or circulating factors.The systems that have been
most extensively studied are cellular and behavioral
models of learning and memory, including long-term
potentiation (LTP),in slices of brain and rodent models
of behavior.The mechanisms identified for learning and
memory most likely also subserve plasticity occurring in
other regions and for other adaptive functions of the
brain. This section will briefly discuss some general
mechanisms and concepts of plasticity.
Mechanisms of acute neural plasticity: synaptic trans-
mission and protein kinases 
The effects underlying the rapid responses to neuronal
activation are mediated by activation of the excitatory
neurotransmitter glutamate and regulation of intracellu-
lar signaling cascades (for a review of acute mechanisms
underlying LTP,see reference 1).Glutamate causes neu-
ronal depolarization via activation of postsynaptic
ionotropic receptors that increase intracellular Na
+.This
leads to the subsequent activation of N-methyl-D-aspar-
tate (NMDA) receptors and the resulting influx of Ca
2+.
Ca
2+ is a major intracellular signaling molecule that acti-
vates a signaling cascade, including activation of Ca
2+/
calmodulin-dependent protein kinase.Within minutes to
hours,activation of glutamate and Ca
2+-dependent path-
ways can result in structural alterations at the level of
dendritic spines.Spines mark the location of glutamate
synapses and have been the subject of intensive investi-
gation for understanding synaptic plasticity.
2 Changes in
the shape and even number of spines can occur very
rapidly (minutes to hours) after glutamate stimulation.
These alterations are made permanent or long-term
when they are stabilized or consolidated,a process that
requires gene expression and protein synthesis.
Mechanisms of long-term plasticity: gene expression and
protein synthesis
The Ca
2+/cyclic adenosine monophosphate (cAMP)
response element (CaRE) binding protein (CREB) is
one of the major transcription factors that mediate the
actions of Ca
2+, as well as cAMP signaling. CREB has
been reported to play a role in both cellular and behav-
ioral models of learning and memory.
3There are a num-
ber of gene targets that are influenced by Ca
2+, cAMP,
and CREB,and the pattern of gene regulation is depen-
dent on the cell type,the length of stimulation,as well as
the magnitude of stimulation. Gene targets that have
been implicated in learning and memory, and are rele-
vant to the effects of stress and antidepressant treat-
ment, are the neurotrophic factors. Of particular inter-
est is brain-derived neurotrophic factor (BDNF),one of
the most abundant neurotrophic factors in the brain.
Altered neural plasticity in response to stress
Recent reports have demonstrated altered molecular
and cellular responses to stress and have contributed to
the hypothesis that altered neural plasticity contributes
to stress-related psychiatric illnesses.Some examples of
stress responses are discussed in this section.
Stress alters learning and memory
Stress is known to significantly influence learning and
memory,and the effects are dependent on the type,dura-
tion,and intensity of the stressor.Emotional arousal can
enhance learning and memory via synaptic plasticity of
amygdala-dependent pathways,and this is thought to be
the basis for intense,long-term memories of traumatic
events and posttraumatic stress disorder.
4,5 However,
stress can also impair subsequent learning and memory
and can even lead to amnesia.
6The influence of stress on
hippocampal-dependent learning is complex and depen-
dent on the type of learning task.
In studies of LTP,a consistent suppression of neural plas-
ticity is observed after exposure to stress or adrenal glu-
cocorticoids.
6,7 In one of these studies,the suppression of
LTP was observed after exposure to an uncontrollable
stressor and correlated with behavioral performance in
a learning and memory task.Giving the animals control
over the stress (ie, the stress could be terminated) did
not lead to reduced LTP or decreased learning and
Pharmacological aspects
158
Selected abbreviations and acronyms
BDNF brain-derived neurotrophic factor
cAMP cyclic adenosine monophosphate
CaRE cAMP response element
CREB cAMP response element binding protein
FGF-2 fibroblast growth factor–2
5-HT 5-hydroxytryptamine (serotonin)
LTP long-term potentiation
NMDA N-methyl-D-aspartate
PDE4 phosphodiesterase type IV
PKA protein kinase
SSRI selective serotonin reuptake inhibitormemory.
8 A role for BDNF in the actions of stress on
LTP has also been suggested.
9 For additional references
and discussion of the effects of stress on learning and
memory,see the reviews in references 4 to 7.
Stress causes atrophy of hippocampal neurons
One of the best-characterized examples of altered struc-
tural plasticity in response to stress is the atrophy of hip-
pocampal neurons, which was first described by
McEwen and colleagues (Figure 1).
10 They found that
repeated restraint stress results in atrophy of the den-
drites of CA3 pyramidal neurons in the hippocampus,
measured as a decrease in the number and length of api-
cal dendrites.
11 The reduction in dendritic arborization
was found to be dependent on long-term,repeated expo-
sure to restraint stress (3 weeks) and to be reversible
when the animals are removed from stress.The atrophy
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Figure 1. Model of hippocampal plasticity showing structural alterations in response to stress: atropy of CA3 pyramidal neurons and decreased neu-
rogenesis of dentate gyrus granule cells. Stress results in powerful effects on the hippocampus, partly because of the high levels of gluco-
corticoid receptors expressed in this brain region. Stress results in at least two major actions in two different subfields of the hippocampus.
Repeated stress causes atrophy or remodeling of CA3 pyramidal neurons, decreasing the number and length of apical dendrites. Administration
of glucocorticoids causes a similar effect, and decreased expression of brain-derived neurotrophic factor (BDNF) could contribute to pyrami-
dal cell atrophy. Stress also decreases the proliferation of newborn granule cells in the dentate gyrus, and glucocorticoid administration mim-
ics this effect. Chronic antidepressant administration can reverse the atrophy of CA3 neurons and block the downregulation of neurogenesis
in the dentate gyrus. The effects of antidepressant treatment occur via acute regulation of serotonin (5-hydroxytryptamine [5-HT]) and nor-
epinephrine (NE) and the regulation of intracellular signaling and gene expression. mf, mossy fiber; sc, Schaffer colaterals.
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scof CA3 pyramidal cells appears to result from the ele-
vation of adrenal glucocorticoids that occurs during
stress because chronic administration of corticosterone,
the active form in rodent,results in a similar decrease in
number and length of dendrites.
12 The actions of stress
and glucocorticoids are blocked by administration of an
NMDA receptor antagonist, indicating that this gluta-
mate receptor is required for atrophy of CA3 neurons.
10
Atrophy of CA3 pyramidal neurons occurs after 2 to 3
weeks of exposure to restraint stress or more long-term
social stress,and has been observed in rodents and tree
shrews.
11-13 In contrast to the atrophy of hippocampus,
recent studies demonstrate that chronic stress causes
hypertrophy of neurons in the amygdala.
14 This study
found chronic immobilization stress increased the den-
dritic arborization of pyramidal neurons in the basolat-
eral amygdala, but decreased dendrite length and
branching in the CA3 pyramidal neurons of the hip-
pocampus.Hypertrophy of the amygdala could underlie
increased learning and memory as a result of stress-
induced emotional arousal, and may be relevant to the
pathophysiology of stress-related disorders, including
anxiety, posttraumatic stress, and depression. Increased
arborization of neurons in the amygdala could thereby
enhance emotional states or disrupt normal processing
of emotional responses.
Stress decreases neurogenesis in the adult 
hippocampus
In addition to regulation of the morphology of neurons
in the hippocampus, stress influences the number of
newborn neurons or neurogenesis in the adult hip-
pocampus
15,16 (Figures 1 and 2).The hippocampus is one
of two brain regions where neurogenesis continues to
occur in adult organism (the other region is in the sub-
ventricular zone). In the hippocampus, neural progeni-
tor cells are found in the subgranular zone,between the
granule cell layer and the hilus.These cells give rise to
newborn cells that migrate into the granule cell layer
and mature into neurons with the morphological and
physiological characteristics of adult granule cells.
17
Interestingly, the process of neurogenesis is highly reg-
ulated by a variety of stimuli and can be considered a
form of neural plasticity. For example, enriched envi-
ronment, exercise, and learning increase neurogenesis,
while aging and exposure to drugs of abuse decrease
neurogenesis.
15,16,18
In addition to these factors, stress also results in a dra-
matic downregulation of neurogenesis in the hippocam-
pus.
10,18 Exposure to just a single stressor is sufficient to
significantly decrease neurogenesis in the adult hip-
pocampus.Adult neurogenesis is decreased by different
types of stress,including subordination stress,
19 predator
odor,
20 maternal separation,
21 and footshock.
22 In addi-
tion,exposure to inescapable stress in the learned help-
lessness model of depression decreases adult neurogen-
esis and this effect correlates with behavioral despair in
this model.
22 Moreover, the reduction in neurogenesis
and the behavioral despair is reversed by antidepressant
treatment.
Regulation of CREB and decreased expression of
BDNF in response to stress
Stress results in a wide range of effects that influence
many different neurotransmitter and neuropeptide sys-
tems, signal transduction pathways, and altered gene
expression.The hallmark of the stress response is acti-
vation of the hypothalamic-pituitary-adrenal (HPA)
axis, which includes increased circulating levels of
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Figure 2. Model demonstrating the regulation of adult neurogenesis in
the hippocampus. Neural progenitor cells are restricted to the
subgranular zone (SGZ) that is located between the granule cell
layer (GCL) and hilus. These progenitor cells give rise to new-
born neurons that migrate into the granule cell layer and mature
into adult neurons. The proliferation and survival of newborn
neurons is subject to change and can be considered a form of
neural plasticity. Neurogenesis is influenced by a number of dif-
ferent stimuli in either a positive or a negative manner as indi-
cated. SSRI, selective serotonin reuptake inhibitor; NE, nora-
drenaline; MAOI, monoamine oxidase inhibitor; ECS,
electroconvulsive seizures; mfp, mossy fiber pathway.
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 • Exerciseadrenal glucocorticoids.The hippocampus contains very
high levels of glucocorticoid receptors and is therefore
significantly impacted by stress.As mentioned above,
studies by McEwen and colleagues have demonstrated
that glucocorticoids contribute to the atrophy and
decreased neurogenesis of hippocampal neurons result-
ing from exposure to stress.
10
In addition, stress is reported to influence CREB and
BDNF in the hippocampus and other brain regions.The
transcriptional activity of CREB is regulated by phos-
phorylation and levels of phospho-CREB are used as an
indirect measure of CREB activation and function
(Figure 3).The regulation of phospho-CREB is complex
and is dependent on the brain region and whether the
stress is acute or chronic.
23-26 Acute stress increases lev-
els of phospho-CREB in many limbic regions associated
with mood disorders and this may represent a normal or
appropriate adaptive responsiveness.
24 In contrast,
chronic stress leads to decreased levels of phospho-
CREB in many limbic brain regions,which could lead to
decreased plasticity and function.
26
Stress has profound effects on the expression of BDNF
in the hippocampus.Levels of BDNF expression in hip-
pocampus are dramatically downregulated by both acute
and chronic stress,and this effect could contribute to the
atrophy and decreased neurogenesis caused by stress
(Figure 1).
27-29The role of other factors that could under-
lie the actions of stress on adult neurogenesis is a sub-
ject of interest and could lead to novel targets for drug
development.
Atrophy of limbic brain structures in
depressed patients
Evidence from basic research studies provide strong
support for the hypothesis that stress-related illnesses
such as depression could include alterations in brain
structure and neural plasticity. Indeed, direct evidence
to support this hypothesis has been provided by brain
imaging and postmortem studies of depressed patients.
Evidence from brain imaging studies
Magnetic resonance imaging studies have demonstrated
that the size of certain brain structures is decreased in
mood disorder patients. In particular, these studies
demonstrate that the volume of the hippocampus is
decreased in patients with depression.
30,31 Reduced hip-
pocampal volume is also observed in patients with post-
traumatic stress disorder (PTSD).
32The reduction in hip-
pocampal volume is directly related to the length of ill-
ness.
33,34 In addition to hippocampus,atrophy of prefrontal
cortex and amygdala—brain regions that control cogni-
tion, mood, and anxiety—has also been reported in
patients with depression or bipolar disorder.
35
Evidence from postmortem studies
Atrophy of hippocampus or other brain regions could
result from loss of cells (neurons or glia) or decreased
size of the cell body or neuronal processes.The most
extensive studies have been conducted on prefrontal and
cingulate cortex and demonstrate that the neuronal
body size and number of glia is decreased in depressed
patients.
36-38 There is much less known about the hip-
pocampus and additional studies will be required to
determine what accounts for the atrophy of hippocam-
pus observed in depressed patients.
Postmortem analysis of CREB and BDNF has also pro-
vided evidence consistent with a loss of neural plasticity
in depression.Levels of CREB are decreased in the cere-
bral cortex of depressed patients or suicide victims.
39,40
Levels of BDNF are also decreased in prefrontal cortex
and hippocampus of depressed patients.
41 Reduced lev-
els of CREB and BDNF, two molecular markers of
neural plasticity,indicate that the ability of limbic brain
structures to mount adaptive responses is compromised
in depressed patients.
Antidepressant treatment increases neural
plasticity
In contrast to the effects of stress, antidepressant treat-
ment results in molecular and cellular responses that
demonstrate an increase in neural plasticity. Moreover,
these studies have paved the way for additional studies
that demonstrate that antidepressant treatment results
in structural remodeling. In many cases, the effects of
antidepressant treatment oppose or reverse the effects
of stress.Taken together, these findings provide addi-
tional support for the hypothesis that neural plasticity
plays a significant role in the treatment, as well as the
pathophysiology of mood disorders.The evidence for
regulation of neural plasticity at the level of neurogen-
esis,signal transduction,and gene expression is discussed
in the second half of this review.
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adult neurogenesis
Neurogenesis is increased by chronic antidepressant
administration
One of the most surprising discoveries of recent times in
the field of depression is that antidepressant treatment
regulates neurogenesis in the adult hippocampus (Figures
1 and 2).In contrast to the actions of stress,chronic anti-
depressant treatment increases the number of newborn
neurons in the adult hippocampus of rodents or tree
shrews.
42,43The upregulation of neurogenesis is dependent
on chronic antidepressant treatment,consistent with the
time course for the therapeutic action of antidepressants.
43
In addition,different classes of antidepressants,including
serotonin (5-hydroxytryptamine [5-HT]) and noradrena-
line reuptake inhibitors,and electroconvulsive seizures are
reported to increase adult neurogenesis.
43-45Antidepressant
treatment influences two important aspects of neurogen-
esis,the rate of cell proliferation (ie,the number of new-
born neurons) and the survival of newborn neurons.
46An
increase in the number of newborn neurons could con-
tribute to the reversal of hippocampal atrophy observed
in depressed patients.
Antidepressant treatment blocks the downregulation
of neurogenesis caused by stress
The influence of antidepressant treatment in the context
of stress has also been examined.These studies demon-
strate that chronic antidepressant treatment can block
or reverse the downregulation of neurogenesis that
results from exposure to stress. Several different types
of stress have been tested,including blockade of intruder
stress,
42 maternal separation,
47 and learned helplessness.
22
In addition,different types of antidepressants have been
tested,including an atypical antidepressant,tianeptine,
42
a selective serotonin reuptake inhibitor (SSRI),
22,47 and
a neurokinin-1 receptor antagonist.
48
The influence of antidepressant treatment on the atrophy
of CA3 pyramidal neurons resulting from chronic expo-
sure to stress has been examined.These studies demon-
strate that chronic administration of tianeptine blocks the
atrophy of CA3 apical dendrites that is caused by stress.
12
Chronic administration of an SSRI antidepressant did not
block the atrophy of CA3 neurons in this study.Analysis
of dendrite branch number and length is tedious and
labor intensive, but additional studies of other antide-
pressants are necessary to determine the relevance of this
effect in the actions of antidepressant treatment.
A functional role for neurogenesis in the action of
antidepressant treatment
A major issue in the field of adult neurogenesis is how
to test the function of newborn neurons.A recent study
has addressed this question by using a combination of
irradiation and mutant mouse approaches.
49 This study
demonstrates that focused irradiation of hippocampus
in the mouse completely blocks neurogenesis and there
was a corresponding blockade of the behavioral actions
of antidepressant treatment in two behavioral models,
novelty suppressed feeding and chronic mild stress. In
addition, Santarelli et al
49 studied the effects of antide-
pressants in mice with a null mutation of the 5-HT1A
receptor, a subtype that has been implicated in the
actions of antidepressant treatment. They found that
upregulation of neurogenesis by chronic administration
of an SSRI was completely blocked in 5-HT1A null
mutant mice, and that the behavioral effects of SSRI
treatment were similarly blocked.These results are the
first evidence that increased neurogenesis is necessary
for an antidepressant response in behavioral models.
There are a few limitations to this study.First,although
novelty-suppressed feeding is responsive to chronic anti-
depressant treatment—and this is why it was chosen—
this paradigm is a better model of anxiety than depres-
sion. Second, although the effects of antidepressant
treatment were blocked, irradiation and 5-HT1A null
mutation alone,in the absence of antidepressant admin-
istration,did not produce a depressive phenotype.This is
consistent with another report demonstrating that
decreased neurogenesis is not correlated with behavior
in the learned helplessness model of depression.
50
Together these studies indicate that neurogenesis is not
required for baseline response. However, it is possible
that intact neurons are sufficient to sustain baseline
response and that more long-term inhibition of neuro-
genesis would be required to influence activity.
The cAMP-CREB cascade and depression
Neural plasticity upon antidepressant treatment is likely
to involve adaptations of multiple intracellular signaling
cascades and even interactions of these pathways. One
Pharmacological aspects
162of the pathways that is regulated by antidepressant treat-
ment and has been demonstrated to contribute to the
actions of chronic antidepressant responses is the
cAMP-CREB cascade, the subject of this section.
However, it is likely that other signaling pathways are
also regulated by—and play a role in—the actions of
antidepressants.For reviews covering other signal trans-
duction pathways,see reference 51 and 52.
Antidepressant treatment upregulates the cAMP-
CREB cascade
Several studies have investigated the influence of anti-
depressant treatment on the cAMP-CREB pathway
(Figure 3).
53,54This work demonstrates that chronic anti-
depressant treatment upregulates the cAMP second-mes-
senger cascade at several different levels.This includes
Neural plasticity and depression - Duman Dialogues in Clinical Neuroscience - Vol 6 . No.2 . 2004
163
Figure 3. Model demonstrating the upregulation of the cyclic adenosine monophosphate (cAMP)–cAMP response element binding protein (CREB)
cascade and expression of brain-derived neurotrophic factor (BDNF) by antidepressant treatment. Chronic, but not acute, antidepressant
treatment upregulates the cAMP-CREB cascade in limbic regions of the brain including the hippocampus and cerebral cortex. This includes
increased coupling of stimulatory G protein (Gs) to adenylyl cyclase, increased levels of cAMP-dependent protein kinase (PKA), and increased
function and expression of CREB. CREB can also be phosphorylated and activated by other kinases, including Ca
2+/calmodulin-dependent
kinase and mitogen-activated protein (MAP) kinase. In this way, CREB could serve as a common target for different types of serotonin 
(5-hydroxytryptamine [5-HT]) and norepinephrine (NE) receptors, including β-adrenergic (βAR), 5-HT7, α1-adrenergic (α1AR), and 5-HT1A
receptor subtypes. One downstream target of CREB that has been shown to have antidepressant effects is BDNF. The BDNF promoter has
at least one Ca
2+/cAMP response element (CaRE) that is regulated by phosphorylation (P) of CREB.
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BDNF geneincreased coupling of the stimulatory G protein to adeny-
lyl cyclase,increased levels of cAMP-dependent protein
kinase (PKA),and increased levels of CREB as well as
phospho-CREB.
55-57 Upregulation of these components of
the cAMP-CREB signaling pathway is dependent on
chronic antidepressant treatment,consistent with the time
course for the therapeutic action of antidepressants. In
addition, upregulation of the cAMP-CREB cascade is
observed in response to chronic administration of differ-
ent classes of antidepressants,indicating that this is a com-
mon target of antidepressant treatment.
In addition to phosphorylation by PKA, CREB is also
phosphorylated by Ca
2+-dependent kinases, such as
Ca
2+/calmodulin-dependent protein kinase,and by mito-
gen-activated protein kinase pathways (Figure 3).In this
way, CREB can serve as a target for multiple signal
transduction pathways and neurotransmitter receptors
that activate these cascades.
Activation of the cAMP-CREB cascade produces an
antidepressant response
Direct evidence for cAMP-CREB signaling in the action
of antidepressant treatment has been tested by pharma-
cological, viral vector, and mutant mouse approaches.
First,drugs that block the breakdown of cAMP produce
an antidepressant response in behavioral models of
depression.
54The primary target for inhibition of cAMP
breakdown is cAMP-specific phosphodiesterase type IV
(PDE4), and rolipram was one of the first selective
PDE4 inhibitors.In addition,we have found that chronic
rolipram administration increases neurogenesis in adult
hippocampus.
46,58
Second, viral expression of CREB in the hippocampus
of rat produces an antidepressant response in the forced
swim and learned helplessness models of depression.
59
However, further studies demonstrated that the effects
of CREB are dependent on the brain region where it is
expressed. For example, expression of CREB in the
nucleus accumbens produces a prodepressant effect,
while expression of a dominant negative mutant of
CREB results in an antidepressant response in the
forced swim test.
60 Transgenic expression of dominant
negative CREB in the nucleus accumbens is consistent
with this effect.
61 The different behavioral effects of
CREB can be explained by different target genes in the
hippocampus (ie,BDNF) versus the nucleus accumbens
(ie,prodynorphin).
Regulation of neurotrophic factors and
depression
The regulation of CREB by antidepressant treatment
indicates that regulation of gene expression also plays a
role in the actions of antidepressants.There have been
many gene targets identified for antidepressants,
51,52 but
BDNF is one that has gained attention and is relevant
to neural plasticity responses to antidepressant medica-
tions. Studies to identify additional gene targets and
gene profiles using gene microarray analysis are cur-
rently being conducted.
Antidepressant treatment upregulates BDNF
Neurotrophic factors were originally identified and stud-
ied for their role in development and neuronal survival.
However,it is now clear that these factors are expressed
in the adult brain,are dynamically regulated by neuronal
activity, and are critical for the survival and function of
adult neurons.On the basis of these considerations,it is
clear why decreased expression of BDNF could have
serious consequences for the function of limbic brain
structures that control mood and cognition.In contrast,
antidepressant treatment results in significant upregula-
tion of BDNF in the hippocampus and cerebral cortex
of rodents.
28,53,54 Increased expression of BDNF is depen-
dent on chronic treatment, and is observed with differ-
ent classes of antidepressants,but not other psychotropic
drugs. The induction of BDNF would be expected to
protect neurons from damage resulting from stress,ele-
vated glucocorticoids,or other types of neuronal insult.
BDNF has antidepressant effects in behavioral models
of depression
The possibility that BDNF contributes to the actions of
antidepressant treatment is supported by behavioral
studies of recombinant BDNF and transgenic mouse
models.Microinfusions of BDNF into the hippocampus
produce an antidepressant-like response in the learned
helplessness and forced swim models of depression.
62
The antidepressant effect of BDNF is observed after a
single infusion,compared with repeated administration
of a chemical antidepressant,and is relatively long-last-
ing (up to 10 days after infusion).Transgenic overex-
pression of a dominant negative mutant of the BDNF
receptor, trkB, in the hippocampus and other forebrain
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164structures is also reported to block the effect of antide-
pressant treatment,demonstrating that BDNF signaling
is necessary for an antidepressant response.
63
Microinfusions of BDNF into the dorsal raphe, a mid-
brain region where 5-HT cell bodies are localized, also
produces an antidepressant response in the learned
helplessness model.
64 Together, these studies indicate
that BDNF could contribute to antidepressant responses
in both forebrain and brain stem structures by affecting
different populations of neurons.Alternatively,it is pos-
sible that microinfusions of BDNF into the hippocam-
pus influence 5-HT neuronal function by acting at presy-
naptic sites,and could therefore enhance 5-HT signaling
as observed after brain stem infusions of BDNF.
64
A neurotrophic hypothesis of depression
Basic research and clinical studies of BDNF have
resulted in a neurotrophic hypothesis of depression and
antidepressant action.
53,54This hypothesis is based in part
on studies demonstrating that stress decreases BDNF,
reduces neurogenesis,and causes atrophy or CA3 pyra-
midal neurons. Brain imaging and postmortem studies
provide additional support, demonstrating atrophy and
cell loss of limbic structures,including the hippocampus,
prefrontal cortex, and amygdala. In contrast, antide-
pressant treatment opposes these effects of stress and
depression, increasing levels of BDNF, increasing neu-
rogenesis,and reversing or blocking the atrophy and cell
loss caused by stress and depression.Additional brain
imaging and postmortem studies, as well as basic
research approaches will be required to further test this
hypothesis.In any case,the studies to date provide com-
pelling evidence that neural plasticity is a critical factor
in the pathophysiology and treatment of depression.
Antidepressants influence other neurotrophic factor
systems
Because of the preclinical and clinical evidence impli-
cating neurotrophic factors in the pathophysiology and
treatment of depression,studies have been conducted to
examine other neurotrophic factor systems. One of the
most robust effects identified to date is that antidepres-
sant treatment increases the expression of fibroblast
growth factor–2 (FGF-2).
65 FGF-2 is known to have a
potent influence on neurogenesis during development
and in the adult brain, and could contribute to antide-
pressant regulation of neurogenesis. Studies are under
way to examine the role of FGF-2 in antidepressant reg-
ulation of neurogenesis and regulation of behavior in
models of depression.Several other growth factors have
been identified by microarray analysis and gene expres-
sion profiling,including vascular endothelial growth fac-
tor,neuritin,and VGF.
66 Studies are currently under way
to determine the functional significance of these growth
factors in models of depression.
Clinical evidence of relevance of neural 
plasticity to antidepressant treatment
Basic research studies clearly demonstrate that antide-
pressant treatment regulates signal transduction, gene
expression, and the cellular responses that represent
neural plasticity.This issue is more difficult to address in
clinical studies, but evidence is slowly accumulating.
Brain imaging studies have been conducted to examine
the influence of antidepressants on the volume of limbic
brain regions. One study demonstrates that hippocam-
pal atrophy is inversely proportional to the length of
time a patient receives antidepressant medication.
67 A
longitudinal study of PTSD patients before and after
antidepressant treatment has found that there is a par-
tial reversal of hippocampal atrophy in patients receiv-
ing medication.
68The latter study demonstrated a corre-
sponding increase in verbal declarative memory in
response to antidepressant treatment.
Evidence at the molecular level is also provided by post-
mortem studies.Levels of CREB immunoreactivity are
increased in patients receiving antidepressant treatment
at the time of death relative to unmedicated patients.
39
In addition, levels of BDNF are increased in patients
taking an antidepressant at the time of death.
59Although
these effects must be replicated and extended (for exam-
ple, to the regulation of neurogenesis) in additional
banks of postmortem tissue, the results are consistent
with the hypothesis that neural plasticity is upregulated
in patients receiving antidepressant medication.
Novel targets for the treatment of depression
The hypothesis that antidepressant treatment increases
neural plasticity provides a number of novel targets for
drug development.However,as with any fundamentally
important mechanism,care must be taken that the drugs
developed for such targets do not interfere with the nor-
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neural plasticity is an exciting area of research for design
of new drugs for a variety of indications,including learn-
ing, memory, cognition, mood, and neurodegenerative
disorders.This section discusses a few of these targets in
the context of the pathways regulated by antidepressants
and stress.
Targets for antidepressant regulation of neurogenesis
Identification of the signal transduction and gene expres-
sion pathways that are responsible for the actions of anti-
depressant regulation of neurogenesis is a subject of
intense investigation.Activation of the cAMP-CREB sig-
naling cascade using either pharmacological or transgenic
approaches is reported to increase both proliferation and
survival of newborn neurons in the hippocampus,
46,58 sup-
porting the possibility that antidepressants increase neu-
rogenesis via regulation of this intracellular pathway.Gene
targets of CREB,as well as other neurotrophic/growth fac-
tors that have been shown to regulate adult neurogenesis,
include BDNF,FGF-2,and insulin-like growth factor–1,to
name but a few.
18 Because antidepressant treatment
increases the expression of both BDNF and FGF-2,these
two factors are currently being investigated.This is just a
partial listing of the signal transduction cascades and fac-
tors that could contribute to antidepressant regulation of
adult neurogenesis.
Targets for regulation of the cAMP-CREB cascade
There are several different sites within the cAMP path-
way that could be targeted for drug development. One
that has already proven to be effective for antidepres-
sant treatment is blockade of PDE4 and the breakdown
of cAMP. Rolipram is a PDE4-selective inhibitor that
has been demonstrated to have antidepressant efficacy
in early clinical trials and behavioral models of depres-
sion.
69,70 However, the clinical use of rolipram has been
limited by its side effects,primarily nausea.
The identification of four different PDE4 isozymes that
are equally inhibited by rolipram raises the possibility
that one of the isozymes underlies the antidepressant
actions of rolipram, while another mediates its side
effects. Studies are currently under way to characterize
the regional distribution and function of the three PDE4
isozymes expressed in brain (PDE4A, PDE4B, and
PDE4D) and the role of these isozymes in the actions of
antidepressant treatment.
71 Studies of mutant mice
demonstrate that null mutation of PDE4D produces an
antidepressant-like phenotype indicating a role for this
isozyme,
72 and similar studies are currently under way
for PDE4A and PDE4B.
BDNF as a target for drug development
The use of BDNF and other neurotrophic factors for the
treatment of neurological disorders has been a subject
of interest for several years, although problems with
delivery, efficacy, and side effects have hampered these
efforts.To more directly replicate the in vivo situation,
it may be possible to stimulate the expression of endoge-
nous BDNF expression by stimulating signaling path-
ways known to regulate this neurotrophic factor. First,
activation of the cAMP-CREB cascade by inhibition of
PDE4 increases the expression of BDNF.
56
Small molecular agonists for neurotransmitter receptors
have also exhibited some promise. Activation of
ionotropic glutamate receptors increases BDNF expres-
sion and could be targeted for the treatment of depres-
sion.
73 One drug that modulates glutamate transmission
and increases BDNF expression is memantine.
74
Riluzole, a sodium channel blocker, also increases
BDNF expression, as well as neurogenesis in adult hip-
pocampus.
75 Specific 5-HT and norepinephrine receptor
subtypes that activate cAMP (eg, β-adrenergic, 5-HT7),
Ca
2+, or mitogen-activated protein kinase (α1-adrener-
gic, 5-HT1A) pathways could also be targets for devel-
opment. Characterization of the antidepressant actions
of these compounds will be needed, as well as identifi-
cation of additional neurotransmitter and signal trans-
duction systems that regulate BDNF.
Conclusions
Studies of the molecular and cellular mechanisms under-
lying neural plasticity responses in learning and mem-
ory, as well as fear, anxiety, depression, and drug abuse
to name but a few, are some of the most exciting and
rapidly advancing areas of research in neuroscience.
Progress in our understanding of neural plasticity has
profound implications for the treatment of a number of
psychiatric and neurodegenerative disorders, and for
enhancing performance in what are considered normal
subjects.One of the promising aspects of neural plastic-
ity is that it implies that the alterations that occur are
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Reversibility of structural as well as functional plasticity
has already been demonstrated in response to pharma-
cological treatments or even behavioral therapy.As the
fundamental mechanisms of neural plasticity are further
elucidated, new targets and paradigms for enhancing
plasticity will be revealed and will lead to more effective
and faster-acting therapeutic interventions. ❏
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Plasticidad neuronal: consecuencias del estrés
y efectos del tratamiento antidepresivo
La plasticidad neuronal está resultando un meca-
nismo fundamental y específico de la función neu-
ronal, lo que permite que el cerebro reciba infor-
mación y ejecute las respuestas de adaptación
apropiadas a los estímulos correspondientes. El
esclarecimiento de los mecanismos moleculares y
celulares que subyacen a la plasticidad neuronal es
uno de los objetivos principales de la investigación
en neurociencias y se han realizado avances signifi-
cativos en esta área en los últimos años. Estos meca-
nismos incluyen la regulación de la transducción de
señales y la expresión génica, como también las
alteraciones estructurales de las espinas neuronales
y sus procesos e incluso el nacimiento de nuevas
neuronas en el cerebro adulto. La alteración de la
plasticidad podría participar en los trastornos psi-
quiátricos y neurológicos. Este artículo revisa la lite-
ratura que demuestra que hay una modificación en
la respuesta de estrés y hay evidencias que el trata-
miento antidepresivo crónico puede revertir o blo-
quear estos efectos, e incluso inducir respuestas
neurales semejantes a la plasticidad. El esclareci-
miento continuo de los mecanismos que subyacen
a la plasticidad neuronal conducirá a blancos para
nuevos fármacos que podrían llegar a constituirse
en intervenciones terapéuticas efectivas y de rápida
acción. 
Neuroplasticité : conséquence du stress et
actions des traitements antidépresseurs
La neuroplasticité se révèle être un mécanisme fon-
damental et déterminant de la fonction neuronale,
permettant au cerveau de recevoir l’information et
d’apporter les réponses adaptatives appropriées aux
stimuli ultérieurs qui s’y rattachent. L’élucidation des
mécanismes moléculaires et cellulaires sous-jacents à
la neuroplasticité est un objectif majeur de la
recherche en neurosciences et des progrès significa-
tifs ont été réalisés ces dernières années. Ces méca-
nismes comprennent la régulation de la transduction
du signal et de l’expression du gène ainsi que les
altérations structurales des prolongements et des
épines dendritiques des neurones et même la nais-
sance de nouveaux neurones dans le cerveau adulte.
L’altération de ces mécanismes pourrait contribuer
aux pathologies psychiatriques et neurologiques. Cet
article passe en revue la littérature pour faire le point
sur les arguments en faveur de l’altération de la plas-
ticité en réponse au stress et de la capacité du trai-
tement antidépresseur au long cours à en inverser
ou neutraliser les effets voire même à susciter des
réponses semblables à celles de la neuroplasticité. La
poursuite des efforts pour élucider les mécanismes
sous-jacents à la neuroplasticité permettra de définir
de nouvelles cibles médicamenteuses et de débou-
cher ainsi sur des interventions thérapeutiques effi-
caces et d’action rapide.
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